9.24
Meiragtx Holdings Plc stock is traded at $9.24, with a volume of 383.90K.
It is down -2.63% in the last 24 hours and down -7.88% over the past month.
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.
See More
Previous Close:
$9.49
Open:
$9.5
24h Volume:
383.90K
Relative Volume:
0.54
Market Cap:
$855.71M
Revenue:
$81.39M
Net Income/Loss:
$-114.20M
P/E Ratio:
-6.4828
EPS:
-1.4253
Net Cash Flow:
$-50.60M
1W Performance:
-1.70%
1M Performance:
-7.88%
6M Performance:
+23.86%
1Y Performance:
+82.61%
Meiragtx Holdings Plc Stock (MGTX) Company Profile
Name
Meiragtx Holdings Plc
Sector
Industry
Phone
646-860-7985
Address
655 THIRD AVENUE, NEW YORK, NY
Compare MGTX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
MGTX
Meiragtx Holdings Plc
|
9.24 | 878.86M | 81.39M | -114.20M | -50.60M | -1.4253 |
|
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
|
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Meiragtx Holdings Plc Stock (MGTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-24-25 | Initiated | H.C. Wainwright | Buy |
| Oct-21-25 | Initiated | Raymond James | Strong Buy |
| Jul-31-24 | Resumed | Chardan Capital Markets | Buy |
| Oct-23-20 | Initiated | RBC Capital Mkts | Outperform |
| Sep-15-20 | Resumed | BofA Securities | Buy |
| Sep-03-19 | Initiated | Piper Jaffray | Overweight |
| Feb-27-19 | Reiterated | Chardan Capital Markets | Buy |
| Jul-03-18 | Initiated | Barclays | Overweight |
| Jul-03-18 | Initiated | BofA/Merrill | Buy |
View All
Meiragtx Holdings Plc Stock (MGTX) Latest News
MeiraGTx Holdings | 4: Statement of changes in beneficial ownership of securities-Officer Wollin Robert J - Moomoo
Chardan Capital Maintains MeiraGTx Holdings (MGTX) Buy Recommendation - MSN
MeiraGTx Holdings PLC (MGTX) reports Q1 loss, lags revenue estimates - MSN
MeiraGTx Holdings stock (US58550P1012): Insider selling draws attention as gene therapy story evolve - AD HOC NEWS
Can MeiraGTx Holdings PLC (MGTX) Stock Double? Cash Runway Offers a Hint - Insider Monkey
Meiragtx president & CEO Forbes Alexandria sells $568,540 in shares - Investing.com India
Insider Sell Alert: Alexandria Forbes Sells 62,000 Shares of Mei - GuruFocus
Meiragtx president & CEO Forbes Alexandria sells $568,540 in shares By Investing.com - Investing.com South Africa
MeiraGTx (MGTX) CEO sells 62,000 shares under Rule 10b5-1 plan - Stock Titan
MGTX (NASDAQ) affiliate lists 62,000-share sale in Form 144 filing - Stock Titan
10 Best Gene Therapy Stocks to Buy in 2026 - Insider Monkey
MeiraGTx Holdings stock (US58550P1012): gene therapy player in focus after recent earnings and partn - AD HOC NEWS
MeiraGTx Holdings plc (NASDAQ:MGTX) First-Quarter Results: Here's What Analysts Are Forecasting For This Year - Sahm
Understanding Momentum Shifts in (MGTX) - Stock Traders Daily
Here's What Analysts Are Forecasting For MeiraGTx Holdings plc (NASDAQ:MGTX) After Its First-Quarter Results - Yahoo Finance
MeiraGTx Falls 5.5% as MGTX Shares Slip, Investors Keep Watch Next Week - TechStock²
Will MeiraGTx Holdings PLC (MGTX) report negative Q1 earnings? What you should know - MSN
MGTX Maintained by RBC Capital -- Price Target Raised to $25.00 - GuruFocus
MeiraGTx (NASDAQ:MGTX) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says - MarketBeat
RBC Capital Maintains MeiraGTx Holdings(MGTX.US) With Buy Rating, Raises Target Price to $25 - Moomoo
RBC Raises Price Target on MeiraGTx Holdings to $25 From $24, Keeps Outperform, Speculative Risk - marketscreener.com
Strength seen in MeiraGTx (MGTX): Can its 6.2% jump turn into more strength? - MSN
MeiraGTx Reports First Quarter 2026 Financial and Operational Results - Investing News Network
MeiraGTx (MGTX) Chief Development Officer listed as insider in new Form 3 - Stock Titan
MeiraGTx (MGTX) CDO awarded 100,000 RSUs and 100,000 stock options - Stock Titan
MeiraGTx (MGTX) Reports Q1 Revenue Figures and Significant Progr - GuruFocus
MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
MeiraGTx Holdings PLC (MGTX) Q4 earnings and revenues surpass estimates - MSN
MeiraGTx Holdings plc Q1 2026 10-Q Report: Financial Results, Risk Factors, and Business Overview - Minichart
MeiraGTx Reports Q1 2026 Results: FDA Breakthrough Therapy, Bota-vec Acquisition, Positive Clinical Data, and $100M Financing - Minichart
MeiraGTx Holdings PLC reports results for the quarter ended March 31Earnings Summary - TradingView
MeiraGTx Holdings Releases Q1 2026 Financial Results - AlphaStreet
MeiraGTx Holdings plc Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Is MeiraGTx (MGTX) a Possible Value Trap After Q1 2026? EPS -$0. - GuruFocus
MeiraGTx Holdings PLC (MGTX) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
MeiraGTx's Q1 Adjusted Loss Widens, Revenue Declines; Share Up Pre-Bell - marketscreener.com
Earnings Flash (MGTX) MeiraGTx Posts Q1 Adjusted Net Loss $0.57 a Share, vs. FactSet Est of $0.75 Loss - marketscreener.com
Earnings Flash (MGTX) MeiraGTx Holdings plc Reports Q1 Revenue $0.3M, vs. FactSet Est of $17.0M - marketscreener.com
MeiraGTx Holdings plc 1Q 2026: Revenue $293K, EPS ($0.57) — 10-Q Summary - TradingView
MeiraGTx (MGTX) deepens Janssen, Lilly and Hologen ties while posting Q1 2026 loss - Stock Titan
MeiraGTx reports Q1 2026 results: $0.3M revenue, $46.3M net loss, $73.8M cash - TradingView
MeiraGTx Holdings 1Q Loss/Shr 57c >MGTX - Moomoo
Regulatory wins and $100M raise reshape MeiraGTx (MGTX) pipeline outlook - Stock Titan
Earnings Flash (MGTX) MeiraGTx Holdings Plc Reports Q1 Revenue $0.3M, Vs. FactSet Est of $17.0M - Moomoo
Press Release: MeiraGTx Reports First Quarter 2026 Financial and Operational Results - Moomoo
MeiraGTx Holdings (NASDAQ:MGTX) Passes Minervini Trend Template and High Growth Momentum Screen - ChartMill
Adage Capital (MGTX) reports 4,000,000-share holding, 4.91% stake - Stock Titan
MeiraGTx Holdings stock (US58550P1012): Q1 earnings report due May 12 - AD HOC NEWS
Number of shareholders of MeiraGTx Holdings Plc – LS:A2JGHF - TradingView
MSN Money - MSN
MeiraGTx Holdings plc (MGTX) Stock Analysis: Unpacking a Promising 188% Upside in Biotech Innovation - DirectorsTalk Interviews
Meiragtx Holdings Plc Stock (MGTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):